Click Here to return To Results

 

Treatment for Cerebral Toxoplasmosis Protects Against Pneumocystis Carinii Pneumonia in patients with AIDS Ann Int Med 115:760-763, Heald,A.,et al, 1991 See this aricle in Pubmed Article Abstract Six of 99(6%)patients with other severe miosis,50 of 240(21%)patients with other severe opportunistic infections,and 8 of 114(6%)patients receiving inhaled pentamidine developed P.carinii pneumonia.Life-table analysis showed that the incidence of pneumonia was substantially lower in patients with toxoplasmosis compared with that in patients with other severe opportunistic infections and was similar to the incidence in patients receiving pentamidine as prophylaxis.Analysis of the medication records from patients with toxoplasmosis showed that pyrimethamine and sulfonamides were administered 50%of the time;pyrimethamine and clindamycin,25%of the time;and pyrimethamine alone,9.9%of the time but that only one of six patients with toxoplasmosis who developed P.carinii pneumonia received pyrimethamine and sulfonamides in the month before diagnosis.Patients with cerebral toxoplasmosis have a low risk for subsequently developing P.carinii pneumonia.This decreased risk is probably the result of chronic suppressive treatment with pyrimethamine and sulfonamides.

Related Tags

(click to filter results - removes previous filter) acquired immunodeficiency syndrome pneumocystis carinii pyrimethamine sulfadiazine toxoplasmosis,acquired toxoplasmosis,CNS treatment of neurologic disorder

Click Here to return To Results